长春瑞滨联用顺铂与吉西他滨联用顺铂治疗晚期非小细胞肺癌的临床观察  

Clinical observation of chemotherapy with NP and GP regimens on advanced non-small cell lung cancer patients

作　　者：任玲[1,2] 夏媛[1,2] 操乐杰[1,2] 

机构地区：[1]安徽医科大学附属省立医院 [2]安徽省立医院干部病房,合肥230001

出　　处：《中国临床保健杂志》2010年第2期124-126,共3页Chinese Journal of Clinical Healthcare

摘　　要：目的探讨NP方案(长春瑞滨联用顺铂)和GP方案(吉西他滨联用顺铂)对晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法回顾分析35例接受化疗的晚期NSCLC患者资料,其中Ⅲ期NSCLC患者19例,占54.3%,Ⅳ期NSCLC患者16例,占45.7%。总结接受化疗方案为NP组和GP组且每个患者至少接受2个周期以上的同一化疗方案的患者资料,观察方案治疗的近期疗效和不良反应。结果NP和GP总的有效率分别为12.5%,10.5%。NP组和GP组的不良反应均在可耐受的范围。结论NP和GP方案均对晚期非小细胞肺癌有效且耐受性较好,可作为晚期初治NSCLC的一线化疗方案。Objective To evaluate the efficacy and toxic reaction of NP and GP regimens in patients with advanced stage non-small cell lung cancer（NSCLC）.Methods The clinical data of 35 patiences with NSCLC,which included 19 cases（54.3%）in stage Ⅲ and 16 patiences（45.7%）in stage Ⅳ.All the patients had accepted the intravenous chemotherapy of NP or GP over 2 cycles at least.The clinical therapeutic effects and adverse effects of NP and GP were recorded.Results The total effective rate of NP and GP were 12.5%（2/16）in NP group and 10.5% （2/19） in GP group.The adverse effects of two regiments were little and tolerable.Conclusion Regimens of NP and GP are both safe and effective in the treatment of advanced stage NSCLC.They could be used as the first regimen of chemotherapy in patients with advanced stage NSCLC.

关 键 词：癌 非小细胞肺 抗肿瘤联合化疗方案 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]